In women undergoing IUI, cetrorelix did not significantly change clinical pregnancy rates versus r-FSH alone (27.6%, n=56 versus 26.5%, n=54, P=0.800).
In plain wordsIn women undergoing IUI, cetrorelix did not significantly change clinical pregnancy rates compared with r-FSH alone.
- Peptide
- Cetrorelix
- Outcome
- No significant changeClinical pregnancy rate
- Study
n = 427
- Comparator
- r-FSH alone
- Analysis
- Primary
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 0.25 mg/dayAs given in this study (human).
Measurements
- Clinical pregnancy rate
- 27.6%
- cetrorelix
- Clinical pregnancies
- 56 women
- cetrorelix
- Clinical pregnancy rate
- 26.5%
- r-FSH alone
- Clinical pregnancies
- 54 women
- r-FSH alone
Source sentences
Clinical pregnancy rate in Groups I and II was 27.6% (n = 56) and 26.5% (n = 54), respectively (P=0.800).
5 context sentences(design, population, supporting numbers)
Primary outcome measure was clinical pregnancy rate.
This was a prospective, randomized case-controlled study.
Four hundred twenty-seven women undergoing IUI following controlled ovarian stimulation with gonadotropins (recombinant follicle-stimulating hormone [r-FSH] 75 IU/day) were randomly divided into two groups.
Women in Group I received GnRH antagonist (Cetrorelix 0.25 mg/day) in a multiple dose flexible protocol.
Women in Group II received r-FSH alone.